Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Design Therapeutics (DSGN) Equity Average (2020 - 2026)

Design Therapeutics' Equity Average history spans 2 years, with the latest figure at $386.8 million for Q4 2021.

  • On a quarterly basis, Equity Average rose 4129.45% to $386.8 million in Q4 2021 year-over-year; TTM through Dec 2021 was $386.8 million, a 4129.45% increase, with the full-year FY2021 number at $185.4 million, changed N/A from a year prior.
  • Equity Average hit $386.8 million in Q4 2021 for Design Therapeutics, down from $396.6 million in the prior quarter.
  • Over the last five years, Equity Average for DSGN hit a ceiling of $404.8 million in Q2 2021 and a floor of -$9.6 million in Q4 2020.